One-year outcomes following drug-eluting balloon use for coronary ostial restenosis  by Lee, Wei-Chieh et al.
IJC Heart & Vasculature 10 (2016) 25–28
Contents lists available at ScienceDirect
IJC Heart & Vasculature
j ou rna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/ i jc -hear t -and-vascu la tureOne-year outcomes following drug-eluting balloon use for coronary
ostial restenosisWei-Chieh Lee 1, Hsiu-Yu Fang 2, Wen-Jung Chung, Shu-Kai Hsueh, Chien-Jen Chen, Cheng-Hsu Yang,
Hon-Kan Yip, Chi-Ling Hang, Chiung-Jen Wu ⁎, Chih-Yuan Fang
Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China⁎ Corresponding author at: Division of Cardiology, De
Chang Gung Memorial Hospital, Kaohsiung 123, Ta
Kaohsiung City 83301, Taiwan, Republic of China.
E-mail address: leeweichieh1217@hotmail.com (C.-J. W
1 Indicates equal contribution as correspondence autho
2 Indicates equal contribution as ﬁrst author.
http://dx.doi.org/10.1016/j.ijcha.2015.11.003
2352-9067/© 2015 The Authors. Published by Elsevier Ira b s t r a c ta r t i c l e i n f oArticle history:
Received 4 November 2015
Accepted 8 November 2015
Available online 19 November 2015
Keywords:
Drug-eluting balloons
Coronary ostial instent restenosis
Coronary ostial interventionAims: The management of ostial lesions is one of the challenges of percutaneous coronary intervention (PCI) in re-
cent medicine. Although stent implantation has increased the accuracy of the results and improved long-term out-
comes, in-stent restenosis (ISR) occurs more frequency following the treatment of ostial lesions than the treatment
of non-ostial lesions. When additional stenting is not desirable, PCI with drug-eluting balloons (DEBs) has emerged
as an adjunctive strategy. However, little data regarding the effects of DEBs in ostial ISR lesions are available. Our
study aimed to assess the efﬁcacy of the use of DEBs in coronary ostial instent restenotic lesions.
Methods and results: FromNovember of 2011 toMay of 2014, 85 patientswere diagnosedwith coronary ostial ISR in
ourhospital. A total of 93 coronary ostial ISR lesionswere treatedwithDEBs.More thanhalf of the studypatients had
comorbidities, including hypertension, diabetes, and hyperlipidemia, 77.6% of the study patients had triple vessel
coronary artery disease, and 54.1% of the study patients had left main coronary artery disease. In our study, target
lesion revascularization were performed in 19.2% in all groups; 11.5% were in the ostial left anterior descending ar-
tery, 29.0%were in the ostial left circumﬂex artery, and21.4%were in the ostial right coronary artery. Across all of the
groups, 24.4% of the patients experienced major adverse cardiac cerebral events.
Conclusion: Percutaneous coronary intervention with drug-eluting balloons is an alternative strategy for coronary
ostial instent restenosis when additional stenting is not desirable.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Flow-limiting ostial coronary lesions are clinically important be-
cause they subtend a large myocardial territory and may induce exten-
sive myocardial ischemia. The diagnosis and treatment of these lesions
have been challenging aspects of percutaneous coronary intervention
(PCI) in recent era. The procedural success and clinical of these lesions
outcomes are inferior to those of non-ostial lesions. The majority of
ostial lesions are due to atherosclerotic coronary artery disease [1].
Fibrocellular and sclerotic fragments are the major tissue components
that are found on histological analyses of specimens removed from
right coronary artery ostial lesions by directional atherectomy, and
lipid-rich components are infrequent [2]. Although stent implantation
has improved the accuracy of the results and the long-term outcomes,
in-stent restenosis (ISR) occurs more frequently following thepartment of Internal Medicine,
Pei Road, Niao Sung District,
u).
r.
eland Ltd. This is an open access artictreatment of ostial lesions that the treatment of non-ostial lesions. ISR
is also related to poor clinical outcomes, particularly ostial restenosis.
According to a previous study of the prevalence of coronary ostial
instent restenosis following the use of CYPHER, TAXUS and BMS, the re-
stenosis rates are 6%, 8%, and 33%, respectively [3]. ‘Stent in stent’ treat-
ment causes lumen loss, and additional stenting may not be a desirable
PCI for ostial ISR. The use of DEBs has emerged as an adjunctive strategy.
ComparedwithDESs, theDEBs offer advantages, such as immediate and
homogeneous drug release in the arterial wall and the absence of poly-
mers that can induce chronic inﬂammatory reactions. To the best of my
knowledge, no studies of strategies for coronary ostial ISR lesions have
been published, and little data about the effect of DEBs in ostial ISR le-
sions are available. To address this gap in the published knowledge,
our study aimed to assess the efﬁcacy of the use of DEB for coronary
ostial instent restenotic lesions.
2. Methods
2.1. Patient collection and groups
FromNovember of 2011 toMay of 2014, a total of 85 patients and 93
ostial ISR lesions were treated with DEBs in our hospital. A total of 28le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics of study patientsa.
Ostial lesion (N = 93)
Patient number 85
Lesion number 93
General demographics
Age (year) 66.76 ± 9.85
Male gender (%) 68.2
Clinical condition
STEMI (%) 1.2
NSTEMI (%) 24.7
Unstable angina (%) 56.5
Stable angina (%) 17.6
Risk factors
Hypertension (%) 90.6
Diabetes (%) 61.2
Current smoker (%) 37.6
Old myocardial infarction (%) 41.2
Old stroke (%) 4.7
PAOD (%) 8.2
Hyperlipidemia (%) 61.8
Heart failure (%) 30.6
Prior CABG (%) 9.4
ESRD on maintenance hemodialysis (%) 32.9
Laboratory examination
Creatinine (mg/dL) (exclude ESRD) 1.36 ± 1.32
Lesion-related artery (%)
Left anterior descending artery 30.1
Left circumﬂex artery 35.5
Right coronary artery 34.4
Characteristics of coronary artery disease
Single- or multiple-vessel disease (%)
Single vessel disease 2.4
Double vessel disease 20
Triple vessel disease 77.6
Left main disease (%) 54.1
Previous stent
Bare metal stent (%) 37.6
Drug eluting stent (%) 62.4
Pre-PCI angiography
Pre-PCI stenosis (%) 77.26 ± 13.43
Pre-PCI MLD (mm) 0.71 ± 0.44
Pre-PCI RLD (mm) 3.10 ± 0.54
Post-PCI angiography
Post-PCI stenosis (%) 17.70 ± 8.71
Post-PCI MLD (mm) 2.59 ± 0.47
Post-PCI RLD (mm) 3.19 ± 0.54
DEB
Diameter (mm) 3.25 ± 0.40
Length (mm) 25.98 ± 4.34
IVUS use (%) 43
Complication of PCI (%) 0
F/U time (days) 601.13 ± 291.06
Data are expressed as mean ± SD or as number (percentage).
a Abbreviation: STEMI: ST segment elevation myocardial infarction; NSTEMI: non ST
segment elevation myocardial infarction; PAOD: peripheral arterial occlusive disease;
CABG: coronary artery bypass grafting; ESRD: end stage renal disease; MLD: minimal
luminal diameter; RLD: reference luminal diameter; IVUS: intravascular ultrasound; PCI:
percutaneous intervention; F/U: follow-up.
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ostial left circumﬂex artery (LCX) instent restenosis lesions and 33 ostial
right coronary artery (RCA) instent restenosis lesions were included.
The general demographics, clinical conditions, associated risk factors,
characteristics of coronary artery disease, previous stents and character-
istics of the DEBs were analyzed. Comprehensive inpatient and outpa-
tient data from medical record abstractions and patient interviews
were collected. The Institutional Review Committee on Human Re-
search of our institution approved the study protocol.
2.2. Deﬁnitions
Ostial coronary lesions were deﬁned as stenotic N50% of the lesion
waswithin 3mmof the oriﬁces of the LAD, or LCX or RCA.Major adverse
cerebral cardiac events (MACCEs) includedmyocardial infarction, target
lesion revascularization, stroke and cardiovascular mortality.
2.3. Procedure and protocol
The SeQuent Please (B Braun Melsungen AG, Melsungen, Germany)
was the only DEB used in our hospital. B. Braun Melsungen AG (Berlin,
Germany) has licensed this technology for use in its SeQuent Please
DEB catheter, but the coating procedure and balloon technology have
been improved. Paccocath coating is stable during ethylene oxide steril-
ization, and the balloon has a shelf life of N1 year. More than 80% of the
drug is retained during balloon delivery to the target lesion, and 10 to
15% of the initial dose is delivered to the vessel wall upon 60-second
inﬂation. The DEBs were inﬂated at the ISR site for 30 to 60 s when
the patients were able to tolerate this treatment.
2.4. Study end-points
The primary end-point of this study was target lesion revasculariza-
tion. The secondary end-points of this studywere myocardial infarction
(ST elevation myocardial infarction and non-ST elevation myocardial
infarction), stroke and cardiovascular mortality.
2.5. Statistical analysis
The data are expressed as percentages and the means ± the stan-
dard deviations. The categorical variables were compared using chi-
square tests. The continuous variableswere compared using an analyses
of variance (ANOVAs) test. The differences in the continuous variables
between the two groups were analyzed using a one-way analyses of
variance. A Kaplan–Meier survival curve was performed for the out-
comes of target lesion revascularization at one-year follow-up duration.
P values below 0.05 were considered statistically signiﬁcant. All statisti-
cal analyses were performed using SPSS 22.0 software (SPSS, Inc.,
Chicago, Illinois).
3. Results
3.1. Baseline characteristics of the study patients (Table 1)
The average age of the patients was 66.76± 9.85 years with a range
of 33 to 89 years, and 68.2% of the patients weremale. Themajor clinical
condition of the patients was unstable angina (56.5%). Other patients
exhibited clinical problem, such as ST elevation myocardial infarction
(STEMI, 1.2%), non-ST elevation myocardial infarction (NSTEMI, 24.7%)
and stable angina (17.6%). The majority of patients had hypertension
(90.6%), diabetes (61.2%) and hyperlipidemia (61.8%). Forty-one point
two percent of the patients hadmedical histories of priormyocardial in-
farction, 30.6% had histories of heart failure, and 32.9% had ESRD. The
average of serum creatinine level of the non-hemodialysis patients
was 1.36 ± 1.32 mg/dL. The lesion-related arteries involved the LAD
(30.1%), LCX (35.5%) and RCA (34.4%). The majority of patients hadmultiple vessel diseases (97.6%) and left main artery disease (54.1%).
Among all patients, 77.6% had triple vessel coronary artery disease,
20% had double vessel coronary artery disease, and 2.4% had single
vessel coronary artery disease. The previously used stents included
bare-metal stents (BMSs, 37.6%) and drug-eluting stents (DESs,
62.4%).
Angiography revealed a pre-PCI stenosis of 77.26 ± 13.43%, a
pre-PCI minimal luminal diameter (MLD) of 0.71 ± 0.44 mm and a
pre-PCI reference luminal diameter (RLD) of 3.19 ± 0.54 mm. The
post-PCI stenosis was 17.70 ± 8.71%, the post-PCI MLD was 2.59 ±
0.47 mm, and the post-PCI RLD was 3.19 ± 0.54 mm. The average DEB
length was 25.98 ± 4.34 mm, and the average DEB diameter was
3.25 ± 0.40 mm. Peri-procedure intravascular ultrasound was utilized
Fig. 1. Kaplan–Meier survival curve for the outcomes of target lesion revascularization at
one-year follow-up duration: There were no signiﬁcant difference (P = 0.526) between
three groups. *Abbreviation: LAD: left anterior descending artery; LCX: left circumﬂex
artery; RCA: right coronary artery; No: number.
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The mean follow-up duration was 601.13 ± 291.06 days.
3.2. One-year clinical outcomes of the study patients (Table 2)
During the one-year follow-up, 14 patients experienced myocardial
infarction as NSTEMI, including 9% of all patients, 10.7% of the LAD pa-
tients, 7.7% of the LCX patients and 9.7% of the RCA patients. Among
all patients, 19.2% underwent target lesion revascularization, including
11.5% of the LAD patients, 29.0% of the LCX patients and 21.4% of the
RCA patients. Only one (1.2%) patient experienced ischemic stroke,
and the patient had a LAD lesion. Only two (2.6%) patients experienced
cardiovascularmortality. One of these patients had a LAD lesion, and the
other had a RCA lesion. The incidence ofMACCEwas 24.4% across all pa-
tients, including 28.6% of the LAD patients, 15.4% of the LCX patients and
32.3% of the RCA patients. The incidence of all-causemortality was 7.7%
across all of the patients, including 10.7% of the LAD patients, 3.8% of the
LCX patients and 6.5% of the RCA patients.
3.3. Comparison of the results of DEB use for BMS and DES ISR
In the previous BMS group, 17.1% of the patients experienced target
lesion restenosis, and the rate of target lesion restenosis in the previous
DES group was 20.6% (p = 0.539).
Kaplan–Meier survival curve for the outcomes of target lesion
revascularization at one-year follow-up duration (Fig. 1)
Between LAD, LCX and RCA ISR groups, no signiﬁcant difference
(P = 0.526) was demonstrated. The ostial LAD ISR lesion had better
result following DEB use.
4. Discussion
Ostial stenosis poses a unique challenge for interventionists. The in-
terventions for ostial stenosis lesions are technically difﬁcult even in
cases of native lesions and especially in cases of restenotic lesions. The
ostial lesions are also more prone to complications that include high
rates of ISR [4]. Ostial ISR is also related to poor prognoses. Iakovou I.
et al. reported that 6.3% patients in a CYPHER group and 28% patients
in a BMS group underwent target vessel revascularizations within a
10-month follow-up [5]. In other study, I-Chang Hsieh et al. reported
that the coronary ostial ISR rate following CYPHER, TAXUS and BMS
use were 6, 8, and 33%, respectively [3]. However, no recent studies
have been published regarding the strategy for the treatment of ostial
ISR.
Additional stentingmay be not a desirable PCI for ostial ISR. Repeat-
ed stenting suffers from the following limitations: 1) nonresorbable
polymers trigger chronic inﬂammation and hypersensitivity reactions
that might contribute to increased risks of late stent thrombosis and
late restenosis [6,7]; 2) repeated stenting might lead to an uneven dis-
tribution of drug release and suboptimal stent geometry [8]; 3) repeatedTable 2
One-year clinical outcomes of study patientsa.
All LAD LCX RCA P value
One-year clinical outcomes
Myocardial infarction (%) 9 7.7 8.3 10.7 0.919
Target-vessel revascularization (%) 19.2 11.5 29.0 21.4 0.273
Stroke (%) 1.2 0 0 3.6 0.405
Cardiovascular mortality (%) 2.6 0 4.2 3.6 0.593
MACCE (%) 24.4 15.4 29.2 28.6 0.426
All-cause mortality (%) 7.7 3.8 8.3 10.7 0.633
Data are expressed as number (percentage).
a Abbreviation: LAD: left anterior descending; LCX: left circumﬂex; RCA: right coronary
artery; MACCE: major adverse cardiac cerebral event.stenting might cause insufﬁcient stent expansion, which has been
shown to be predictive of recurrent restenosis [9]; and 4) repeated
stenting is problematic because the treatments for recurrent restenosis
are limited due to the presence of multiple layers of metal in the coro-
nary artery. DEBs allow for immediate and homogenous drug transfer
to the vessel wall without any polymers or a sustained-release mecha-
nism. The absence of a stent ensures that the original anatomies of the
arteries are not altered. The advantage of DEB is that DEB use does to
cause lumen loss because there is no stent structure. From this perspec-
tive, the use of a DEB might be the next preferred strategy for the treat-
ment of ostial ISR. Paclitaxel has been identiﬁed as the primary drug for
use in DEBs due to its rapid uptake and prolonged retention [10].
In a previous study, B. Scheller et al. reported a 4% restenosis rate fol-
lowing DEB at one year and a 6% rate of restenosis at two years [11].
Martin Unverdorben et al. stated that the treatment of coronary ISR
with the paclitaxel-coated balloons is at least as efﬁcacious and well-
tolerated as the paclitaxel-eluting stents. DEB use has been shown to
result in less lumen loss and to be related to the need for target lesion
revascularization [12]. The outcome of DEB use for BMS ISR is better
than that of DEB use for DES ISR [13]. In our study, the restenosis rate
was still lower in the BMS ISR than the DES ISR patients following DEB
use. We still found that restenosis occurred in a greater proportion of
ostial ISR patients following DEB use. This result may be related to the
problem of ostial lesions, which is atherosclerotic change.
In our study, all patients were diagnosed with ostial ISR and exhibit-
ed multiple risk factors. The majority of patients had hypertension
(90.6%), diabetes (61.2%) and hyperlipidemia (61.8%). Moreover,
41.2% of the patients had medical histories of prior myocardial infarc-
tions, 30.6% had histories of heart failure, and 32.9% had ESRD. Among
all patients, 25.9% had experienced STEMI and NSTEMI. The majority
of the patients had multiple vessel disease (97.6%) and left main artery
disease (54.1%). DEBs with prolonged inﬂation for 1 min were used to
treat ostial ISR according to the patients' abilities to tolerate this treat-
ment. After one-year of follow-up, 19.2% of all patients, 11.5% of the
LAD patients, 29.0% of the LCX patients and 21.4% of the RCA patients
underwent target lesion revascularization. Cardiovascular mortalities
were low at 2.6% of all patients, 3.6% of the LAD patients, 0% of the LCX
patients and 3.2% of the RCA patients. To the best of my knowledge,
28 W.-C. Lee et al. / IJC Heart & Vasculature 10 (2016) 25–28no study has reported the results of the use of balloon angioplasty and
stenting for ostial ISR. We have described our experiences related to
the results following the use of DEBs for ostial ISR. Although restenosis
occurred in approximately one-ﬁfth of the patients, we still consider
DEB to be an alternative strategy for coronary ostial ISRwhen additional
stenting is not desirable.
4.1. Limitation
This studywas a retrospective report and included only onemedical
center. All of the patients did not receive follow-up coronary angiogra-
phy to detect target lesion restenosis. We arranged for follow-up
coronary angiographies andnon-invasive examinations, such as treadmill
tests and thallium scans, according to the patients' symptoms. Wemight
have underestimated the occurrence of target lesion restenosis.
5. Conclusions
Percutaneous coronary interventions with drug-eluting balloons
are an alternative strategy for coronary ostial instent restenosis when
additional stenting is not desirable.
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